ABSTRACT
Three-dimensional printed drug development is nowadays an active area in the pharmaceutical industry, where the search for an appropriate edible carrier that permits the thermal processing of the mixture at temperature levels that are safe for the drug is an important field of study. Here, potato starch and hydroxypropyl cellulose based mixtures loaded with paracetamol up to 50% in weight were processed by hot melt extrusion at 85 °C to test their suitability to be thermally processed. The extruded mixtures were tested by liquid chromatography to analyze their release curves and were thermally characterized. The drug recovery was observed to be highly dependent on the initial moisture level of the mixture, the samples being prepared with an addition of water at a ratio of 3% in weight proportional to the starch amount, highly soluble and easy to extrude. The release curves showed a slow and steady drug liberation compared to a commercially available paracetamol tablet, reaching the 100% of recovery at 60 min. The samples aged for 6 weeks showed slower drug release curves compared to fresh samples, this effect being attributable to the loss of moisture. The paracetamol loaded mixture in powder form was used to print pills with different sizes and geometries in a fused deposition modelling three-dimensional printer modified with a commercially available powder extrusion head, showing the potential of this formulation for use in personalized medicine.
ABSTRACT
Ambrisentan is a highly selective endothelin-1 type A receptor antagonist indicated for use in the treatment of pulmonary hypertension. In this study an assay was developed and validated for the quantification of total and unbound (free) concentrations of ambrisentan in human plasma. Plasma samples were dialysed against phosphate buffered saline in a rapid equilibrium dialysis device to obtain dialysate and plasma for unbound and total ambrisentan, respectively. Subsequently, ambrisentan and deuterated ambrisentan (internal standard) were extracted from plasma or plasma dialysate by solid-phase extraction and separated by ultra performance liquid chromatography using on a reversed-phase C18 column. Detection was conducted with a tandem mass spectrometer with an electrospray ionization source and analysed in positive ion mode with multiple reaction monitoring. Calibration curves were generated over a linear concentration range of 0.1-200â¯ng/mL in plasma and 0.1-10â¯ng/mL in plasma ultrafiltrate; with a recovery for ambrisentan of 69.4% and 77.5%, respectively. This assay has been shown to be reproducible and sensitive. The lower limit of quantification in both cases was 0.1â¯ng/mL; reaching a sensitivity not previously described in the literature. The inter- and intra-batch precision and accuracy were in both cases ≤±15%. The procedure was applied to assess total and free plasma concentrations of ambrisentan in healthy volunteers. Plasma protein binding of ambrisentan was approximately 99%.
Subject(s)
Antihypertensive Agents/blood , Chromatography, Liquid/methods , Dialysis/methods , Phenylpropionates/blood , Pyridazines/blood , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry , Calibration , Chromatography, Liquid/standards , Dialysis/standards , Humans , Limit of Detection , Linear Models , Protein Binding , Reference Standards , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization/standards , Tandem Mass Spectrometry/standardsABSTRACT
BACKGROUND: Palonosetron is a potent second generation 5- hydroxytryptamine-3 selective antagonist which can be administered by either intravenous (IV) or oral routes, but subcutaneous (SC) administration of palonosetron has never been studied, even though it could have useful clinical applications. In this study, we evaluate the bioavailability of SC palonosetron. PATIENTS AND METHODS: Patients treated with platinum-based chemotherapy were randomized to receive SC or IV palonosetron, followed by the alternative route in a crossover manner, during the first two cycles of chemotherapy. Blood samples were collected at baseline and 10, 15, 30, 45, 60, 90 minutes and 2, 3, 4, 6, 8, 12 and 24 h after palonosetron administration. Urine was collected during 12 hours following palonosetron. We compared pharmacokinetic parameters including AUC0-24h, t1/2, and Cmax observed with each route of administration by analysis of variance (ANOVA). RESULTS: From October 2009 to July 2010, 25 evaluable patients were included. AUC0-24h for IV and SC palonosetron were respectively 14.1 and 12.7 ng × h/ml (p=0.160). Bioavalability of SC palonosetron was 118% (95% IC: 69-168). Cmax was lower with SC than with IV route and was reached 15 minutes following SC administration. CONCLUSIONS: Palonosetron bioavailability was similar when administered by either SC or IV route. This new route of administration might be specially useful for outpatient management of emesis and for administration of oral chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov NCT01046240.
Subject(s)
Antiemetics/administration & dosage , Isoquinolines/administration & dosage , Isoquinolines/pharmacokinetics , Neoplasms/complications , Quinuclidines/administration & dosage , Quinuclidines/pharmacokinetics , Vomiting/drug therapy , Vomiting/etiology , Administration, Intravenous , Adult , Aged , Antiemetics/adverse effects , Antiemetics/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Female , Humans , Injections, Subcutaneous , Isoquinolines/adverse effects , Male , Middle Aged , Neoplasms/drug therapy , Palonosetron , Platinum/administration & dosage , Quinuclidines/adverse effects , Treatment OutcomeABSTRACT
The clinical management of human brucellosis is still challenging and demands in vitro active antibiotics capable of targeting the pathogen-harboring intracellular compartments. A sustained release of the antibiotic at the site of infection would make it possible to reduce the number of required doses and thus the treatment-associated toxicity. In this study, a hydrophobically modified gentamicin, gentamicin-AOT [AOT is bis(2-ethylhexyl) sulfosuccinate sodium salt], was either microstructured or encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The efficacy of the formulations developed was studied both in vitro and in vivo. Gentamicin formulations reduced Brucella infection in experimentally infected THP-1 monocytes (>2-log10 unit reduction) when using clinically relevant concentrations (18 mg/liter). Moreover, in vivo studies demonstrated that gentamicin-AOT-loaded nanoparticles efficiently targeted the drug both to the liver and the spleen and maintained an antibiotic therapeutic concentration for up to 4 days in both organs. This resulted in an improved efficacy of the antibiotic in experimentally infected mice. Thus, while 14 doses of free gentamicin did not alter the course of the infection, only 4 doses of gentamicin-AOT-loaded nanoparticles reduced the splenic infection by 3.23 logs and eliminated it from 50% of the infected mice with no evidence of adverse toxic effects. These results strongly suggest that PLGA nanoparticles containing chemically modified hydrophobic gentamicin may be a promising alternative for the treatment of human brucellosis.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Brucellosis/drug therapy , Gentamicins/administration & dosage , Nanoparticles , Animals , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Brucella melitensis/drug effects , Cell Line , Drug Carriers , Female , Gentamicins/adverse effects , Gentamicins/pharmacokinetics , Gentamicins/pharmacology , Humans , Hydrophobic and Hydrophilic Interactions , Lactic Acid , Macrophages/microbiology , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid CopolymerABSTRACT
Diosmetin (3',5,7-trihydroxy-4'-methoxyflavone) is the aglycone of the flavonoid glycoside diosmin (3',5,7-trihydroxy-4'-methoxyflavone-7-ramnoglucoside). Diosmin is hydrolyzed by enzymes of intestinal micro flora before absorption of its aglycone diosmetin. A specific, sensitive, precise, accurate and robust HPLC assay for the simultaneous determination of diosmin and diosmetin in human plasma was developed and validated. Plasma samples were incubated with beta-glucuronidase/sulphatase. The analytes were isolated by liquid-liquid extraction with tert-butyl methyl ether at pH 2, and separated on a C(18) reversed-phase column using a mixture of methanol/1% formic acid (58:42, v/v) at a flow rate of 0.5ml/min. APCI in the positive ion mode and multiple reaction monitoring (MRM) method was employed. The selected transitions for diosmin, diosmetin and the internal standard (7-ethoxycoumarin) at m/z were: 609.0-->463.0, 301.2-->286.1 and 191, respectively. A good linearity was found in the range of 0.25-500ng/ml (R(2)>0.992) for both compounds. The intra-batch assay precision (CV) for diosmin and diosmetin ranged from 1.5% to 11.2% and from 2.8% to 12.5%, respectively, and the inter-batch precision were from 5.2% to 11.5% and 8.5% to 9.8%, respectively. The accuracy was well within the acceptable range the accuracies (from -2.7% to 4.2% and -1.6% to 3.5% for diosmin and diosmetin, respectively). The mean recoveries of diosmin, diosmetin and the internal standard were 87.5%, 89.2% and 67.2%. Stability studies showed that diosmin and diosmetin were stable in different conditions. Finally, the method was successfully applied to the pharmacokinetic study of diosmin in healthy volunteers following a single oral administration (Daflon).
Subject(s)
Cardiovascular Agents/blood , Chromatography, High Pressure Liquid , Chromatography, Reverse-Phase , Diosmin/blood , Flavonoids/blood , Tandem Mass Spectrometry , Administration, Oral , Atmospheric Pressure , Cardiovascular Agents/administration & dosage , Cardiovascular Agents/pharmacokinetics , Chromatography, High Pressure Liquid/standards , Chromatography, Reverse-Phase/standards , Diosmin/administration & dosage , Diosmin/pharmacokinetics , Drug Stability , Flavonoids/administration & dosage , Flavonoids/pharmacokinetics , Glucuronidase/metabolism , Humans , Hydrolysis , Reference Standards , Reproducibility of Results , Sulfatases/metabolism , Tandem Mass Spectrometry/standardsABSTRACT
This work describes the preparation, characterization and evaluation of the nanoparticles formed by the copolymer of methyl vinyl ether and maleic anhydride (Gantrez) AN) and cyclodextrins, including beta-cyclodextrin (CD) hydroxypropyl-beta-cyclodextrin (HPCD) and 6-monodeoxy-6-monoamino-beta-cyclodextrin (NHCD). The cyclodextrin-poly(anhydride) nanoparticles were prepared by a solvent displacement method and characterized by measuring the size, zeta potential, morphology and composition. For bioadhesion studies, nanoparticles were fluorescently labelled with rhodamine B isothiocianate (RBITC). For in vivo imaging biodistribution studies, (99m)Tc-labelled nanoparticles were used. Nanoparticles displayed a size of about 150nm and a cyclodextrin content which was found optimal under the following experimental conditions: cyclodextrin/poly(anhydride) ratio of 0.25 by weight, 30min of incubation time between the cyclodextrin and the polymer. Moreover, the oligosaccharide content was higher with CD than with NHCD and HPCD. Overall, cyclodextrin-poly(anhydride) nanoparticles displayed homogeneous bioadhesive interactions within the gut. The intensity of these interactions was higher than for control nanoparticles. The high bioadhesive capacity was observed for HPCD-NP and NHCD-NP which can be related with their rough morphology and, thus, a higher specific surface than for smooth nanoparticles (CD-NP). Finally, from in vivo studies, no evidence of translocation of distribution to other organs was observed when these nanoparticles were orally administered.
Subject(s)
Cyclodextrins/chemistry , Cyclodextrins/pharmacokinetics , 2-Hydroxypropyl-beta-cyclodextrin , Adhesives , Animals , Drug Carriers , Electrochemistry , Fluorescent Dyes , Gastrointestinal Transit , Isotope Labeling , Kinetics , Male , Maleic Anhydrides , Microscopy, Electron, Scanning , Microscopy, Fluorescence , Nanoparticles , Particle Size , Rats , Rats, Wistar , Rhodamines , Technetium , Tissue Distribution , beta-CyclodextrinsABSTRACT
A new method for the quantitative analysis of clindamycin in human plasma and saliva by liquid chromatography/electrospray ionisation tandem mass spectrometry (LC/ESI-MS/MS) has been developed using a rapid resolution C18 column (2.1 mm x 30 mm x 3.5 microm). A simple deproteinization procedure was applied to the samples before analysis. Multiple reaction monitoring (MRM) mode of precursor-product ion transitions for clindamycin (425.1/126.1) and the internal standard, lincomycin (407.2/126.0) was used. Chromatographic separation was achieved at 0.6 ml/min in less than 1.5 min, with improved peak resolution and sensitivity between drug and internal standard. The assay exhibited a linear dynamic range between 0.05 and 15.0 microg/ml and gave a determination coefficient of 0.991 or better. The limit of quantification of the method was 10 ng/ml in both biological samples. Intra-day and inter-day precision ranged from 7.5% to 11.5%. Good accuracy was observed for both the intra-day and inter-day assays (R.S.D. below +/-4%). The suitability of the developed method for the analysis of clindamycin in plasma and saliva samples was demonstrated by the measure of clindamycin in samples taken up to 6h after oral and intravenous administration of this drug in infectious patients.
Subject(s)
Anti-Bacterial Agents/analysis , Chromatography, High Pressure Liquid/methods , Clindamycin/analysis , Saliva/chemistry , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Bacterial Infections/drug therapy , Clindamycin/administration & dosage , Clindamycin/blood , Humans , Reference Standards , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization/methods , Tandem Mass Spectrometry , Time FactorsABSTRACT
Triflusal (CAS 322-79-2) is an antiplatelet agent related to salicylates used in several European and Latin American countries in the treatment of cardiovascular diseases. The aim of this paper was to evaluate the bioequivalence of triflusal derived from two preparations using both parent drug and metabolite pharmacokinetic data. The bioavailabolity was measured in 24 healthy male Caucasian volunteers following a single oral dose (600 mg) of the test or reference products in the fasting state. Blood samples were collected for 120 h. Plasma concentrations of triflusal and its metabolite 3-hydroxy-4-trifluoromethylbenzoic acid (HTB) were analyzed by high-performance liquid chromatography with UV and fluorescence detection, respectively. The non-compartmental method was used for pharmacokinetic analysis. Log-transformed Cmax, AUC0-t and AUC0-infinity were tested for bioequivalence using ANOVA and Schuirmann's two-one sided t-test. Tmax was analyzed by nonparametric pharmacokinetic parameters of triflusal and HTB derived from the two formulations were nearly consistent with previous observations. Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 +/- 11.41 vs 14.48 +/- 7.22 mg/l), AUC0-t (18.43 +/- 10.91 vs 16.22 +/- 7.58 mg/l per hour), Tmax (1 range 0.25-2h vs 0.875 range 0.25-1.5 h), and t(1/2) (0.49 +/- 00.27 vs 0.76 +/- 0.64). HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 +/- 23.05 vs 65.51 +/- 19.44 mg/l), AUC0-t (2748.18 +/- 971.91 vs 2877.97 +/- 881.2 h x mg/l), AUC0-infinity (3350.15 +/- 1182.62 vs 3372.49 +/- 1110.35 h x mg/l), Tmax (2 range 1-10 h vs 2 range 0.75-12 h), and t(1/2) (42.19 +/- 7.82 vs 43.13 +/- 6.56 h). 90% of confidence intervals for the test/reference ratio of Cmax AUC0-t and AUC0-infinity derived from both triflusal and HTB were found within the range of 80%-125% acceptable for bioequivalence. No significant difference was found between the Tmax values for triflusal and HTB. It was concluded that the two preparations are bioequivalent and may be prescribed interchangeably.
Subject(s)
Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/pharmacokinetics , Salicylates/administration & dosage , Salicylates/pharmacokinetics , Adolescent , Adult , Area Under Curve , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Platelet Aggregation Inhibitors/adverse effects , Reference Standards , Salicylates/adverse effects , Spectrometry, Fluorescence , Spectrophotometry, Ultraviolet , Therapeutic EquivalencyABSTRACT
OBJECTIVE: This study aimed to investigate, in healthy volunteers, the relationship between the plasma concentrations of the alpha(1)-adrenoceptor antagonist terazosin and its effects on arterial blood pressure after a single oral administration of terazosin 2 mg. M ethods: Twenty-four healthy volunteers participated in this study. Pharmacokinetic and pharmacodynamic modeling were performed subject by subject. First, plasma concentrations were fitted according to a one-compartment model with first-order absorption and monoexponential elimination. Then the maximum drug-induced decrease (E(max)) effect compartment-model was developed to describe the pharmacodynamic relationships between systolic and diastolic blood pressure and plasma concentrations using the pharmacokinetic parameters that were previously estimated. RESULTS: For systolic blood pressure, E(max) was 29.9 +/- 10.6 mmHg. The corresponding value for decrease in diastolic blood pressure was 39.7 +/- 8.6 mmHg. The effects of terazosin on systolic and diastolic blood pressure could be quantified by an inhibitory E(max) effect compartment model. The obtained first-order rate constant values (0.40 +/- 0.006 h(-)(1) for systolic blood pressure and 0.47 +/- 0.012 h(-)(1) for diastolic blood pressure) were consistent with the rapid development of pharmacological effect. EC(50) (concentration of terazosin that induces an effect at 50% of E(max) values) values were similar for systolic (29.9 +/- 4.3 microg/L) and diastolic (28.7 +/- 4.0 microg/L) blood pressure. A decrease in diastolic blood pressure was the most sensitive response after oral administration of a single dose of terazosin. CONCLUSION: The direct haemodynamic effects of terazosin can be characterized by an E(max) effect compartment model.
Subject(s)
Adrenergic alpha-Antagonists/pharmacokinetics , Blood Pressure/drug effects , Prazosin/analogs & derivatives , Abdominal Pain/chemically induced , Administration, Oral , Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Antagonists/administration & dosage , Adrenergic alpha-Antagonists/pharmacology , Adult , Algorithms , Area Under Curve , Chromatography, High Pressure Liquid , Dizziness/chemically induced , Dose-Response Relationship, Drug , Female , Half-Life , Headache/chemically induced , Heart Rate/drug effects , Humans , Male , Prazosin/blood , Prazosin/pharmacokinetics , Prazosin/pharmacology , Tachycardia/chemically induced , Time FactorsABSTRACT
Gentamicin is an aminoglycoside with a wide spectrum of antibacterial activity. However, as a highly water-soluble drug, it penetrates cells poorly. This constitutes a particularly important drawback for treating intracellular bacterial infections. This major hurdle may be solved by the use of vectors to deliver and target bioactive agents to the intracellular sites of infection. Thus, in the case of antimicrobials, drug delivery systems may help to increase their therapeutic index in intracellular locations. The development and evolution of pharmaceutical forms of gentamicin for the parenteral treatment of intracellular pathogens is reviewed in this paper.
Subject(s)
Bacterial Infections/drug therapy , Drug Delivery Systems/methods , Gentamicins/administration & dosage , Animals , Drug Carriers/chemical synthesis , Drug Carriers/chemistry , Gentamicins/chemistry , Gentamicins/therapeutic use , Humans , Infusions, Parenteral , Liposomes , Nanoparticles/chemistryABSTRACT
A rapid and precise HPLC method with evaporative light scattering detection (ELSD) for the separation and quantification of polyethyleneglycol 2000 (PEG 2000), polyethyleneglycol 6000 (PEG 6000) and poly(methyl vinyl ether-co-maleic anhydride) (Gantrez) in a nanosized pharmaceutical formulation has been developed. Separation was carried out on a PL aquagel-OH 30,8 microm column (300 mm x 7.5 mm), in a gradient elution with methanol-water as mobile phase at a flow rate of 1 ml/min. Quantification was determined in supernatants of PEGylated nanoparticles and the quantification limits were found to be 0.075 mg/ml for polyethyleneglycols and 0.25 mg/ml for Gantrez. The precision did not exceed 8% and accuracy range for PEGs (-11.50 and 10.61%) and Gantrez (-12.18 and 14.81%) were always within the acceptable limits. The amount of polyethyleneglycol associated to nanoparticles was also calculated by a Nuclear Magnetic Resonance Method ((1)H NMR). Likely, for both PEGs, a good relationship between both techniques was found. In summary, the developed HPLC technique provides an alternative for the routine and rapid analysis of PEGs and Gantrez in nanoparticle formulations.
Subject(s)
Chromatography, High Pressure Liquid/methods , Maleates/analysis , Nanoparticles/analysis , Pharmaceutical Preparations/analysis , Polyethylene Glycols/analysis , Polyvinyls/analysis , Light , Magnetic Resonance Spectroscopy , Maleates/chemistry , Molecular Weight , Nanoparticles/chemistry , Particle Size , Pharmaceutical Preparations/chemistry , Polyethylene Glycols/chemistry , Polyvinyls/chemistry , Reproducibility of Results , Scattering, Radiation , Time Factors , VolatilizationABSTRACT
The kinetics of tramadol enantiomers are stereoselective when doses of the racemic drug are given orally. To document whether the route of administration determines the stereoselective kinetics of tramadol enantiomers, healthy volunteers received 100 mg oral or intravenous doses of racemic tramadol, and serial blood samples were obtained to assay tramadol enantiomers and their main phase I metabolites, O-demethyltramadol and N-demethyltramadol. To assess accurately the involvement of their metabolites in the pharmacokinetics of tramadol, it is essential to determine the rate and extent of the formation of the enantiomers of these metabolites. A simultaneous pharmacokinetic model describing the plasma concentration-curves of the generated metabolites and the parent compounds after intravenous and oral drug administration is developed and presented. Tramadol and O-demethyltramadol were the major compounds detected in plasma after intravenous administration. Nevertheless, the N-demethylation of tramadol showed a significant increase when the oral route was used. After both oral and intravenous doses, the kinetics of the tramadol enantiomers were stereoselective. The AUC for (R )-(+)-tramadol was greater than the AUC for (S)-(-)-tramadol. The formation of N-demethyltramadol also was enantioselective after oral administration of racemic tramadol, with a greater AUC for (R)-(+)-N-demethyltramadol than for (S)-(-)-N-demethyltramadol. In the opposite form, (S)-(-)-O-demethyltramadol was formed faster than (R)-(+)-O-demethyltramadol. The metabolism of tramadol was also route-dependent with a different enantiomeric ratio for tramadol and its main phase I metabolites after intravenous and oral administration. The disposition of N-demethyltramadol was concentration-dependent.
Subject(s)
Analgesics, Opioid/pharmacokinetics , Models, Biological , Tramadol/pharmacokinetics , Administration, Oral , Adult , Analgesics, Opioid/administration & dosage , Analgesics, Opioid/blood , Female , Humans , Infusions, Intravenous , Male , Stereoisomerism , Tramadol/administration & dosage , Tramadol/analogs & derivatives , Tramadol/bloodABSTRACT
OBJECTIVE: Our objective was to evaluate the effect of CYP2D6 phenotype in the enantioselective metabolism of tramadol in Spanish healthy human volunteers. METHODS: A single oral 100mg dose of racemic tramadol was administered to five subjects who were poor metabolizers (PMs) and 19 subjects who were extensive metabolizers (EMs), whose phenotypes were determined by the use of the racemic tramadol metabolic rate. The pharmacokinetic parameters were estimated from plasma concentrations of the enantiomers of tramadol and their main phase I metabolites, O-desmethyltramadol (M1) and N-desmethyltramadol (M2). Epinephrine plasma concentrations were also determinated. RESULTS: The plasma concentrations of both tramadol enantiomers were consistently higher in PMs than in EMs of CYP2D6, with 1.98- and 1.74-fold differences in the mean area under the plasma concentration-time curves (AUC), respectively. The values for oral clearance of (+)- and (--)-tramadol were 1.91- and 1.71-fold greater in PMs, which were related to differences in both O-desmethylation and N-desmethylation in the two CYP2D6 metabolizer phenotypes. The mean AUC values of (+)-M1 and (--)-M1 were 4.33- and 0.89-fold greater in EMs, and it was related to similar differences in the formation rate constant. On the other hand, the differences were 7.40- and 8.69-fold greater in PMs for M2 enantiomers due to the involvement of CYP2D6 in their subsequent biotransformation. The time course of epinephrine systemic concentrations was completely different between both groups of metabolizers. In EMs plasma concentrations of epinephrine increased after tramadol administration whereas in PMs no effect was observed. CONCLUSIONS: The polymorphic CYP2D6 appears to be a major enzyme involved in the metabolism of tramadol enantiomers. The N-desmethylation pathway was indirectly affected by CYP2D6 phenotypic differences. Epinephrine showed a good correlation with the pharmacokinetics of the opioid component of tramadol, (+)-M1 and was found to be useful for its pharmacodynamic profiling.
Subject(s)
Analgesics, Opioid/pharmacokinetics , Cytochrome P-450 CYP2D6/genetics , Polymorphism, Genetic , Tramadol/pharmacokinetics , Adult , Analgesics, Opioid/blood , Analgesics, Opioid/chemistry , Area Under Curve , Epinephrine/blood , Female , Humans , Male , Metabolic Detoxication, Phase I , Phenotype , Stereoisomerism , Tramadol/blood , Tramadol/chemistryABSTRACT
Brucellosis is a highly contagious bacterial zoonosis that affects millions of people worldwide. Brucella is highly infectious, especially when aerosolized. The infection induces severe protracted diseases, which are both debilitating and incapacitating, hence, Brucella melitensis has been considered a potential biological warfare agent. In the battle against Brucella, it is crucial to know its chemical-structure and biochemistry-metabolic characteristics. It is well known that Brucella, as well as many other intracellular bacterial pathogens, has evolved to survive and even proliferate within monocytes and macrophages cells. Depending on the route of entry (complement, Fc, lectin or fibronectin receptors), the fate of the bacteria will vary; it may even segregate from the endocytic route towards the endoplasmic reticulum. This intracellular "non regular" behaviour of Brucella makes treatment difficult. Most antibiotics, although effective in vitro, do not actively pass through cellular membranes, or, once inside, may not reach the discrete intracellular niche where the bacteria is hidden. Therefore, complete eradication of the microorganisms is difficult to achieve, and the incidence of relapses is rather high. Taking these data into consideration, this review will evaluate the past, current and new trends in the control of brucellosis, paying special attention to the drug delivery systems as potential vectors for targeting these intracellular sites where the organisms are located.
Subject(s)
Anti-Bacterial Agents , Brucella/drug effects , Brucellosis/drug therapy , Drug Delivery Systems/methods , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Brucella/isolation & purification , Brucellosis/microbiology , Humans , Macrophages/metabolism , Macrophages/microbiology , Monocytes/metabolism , Monocytes/microbiologyABSTRACT
The design of bioadhesive nanoparticles (NPs) for targeting specific sites within the gut remains a major challenge. One possible strategy to solve this problem may be the use of pegylated NPs. In general, these carriers display different bioadhesive properties to nondecorated NPs. Thus, pegylated NPs show a higher ability to interact with the small intestine mucosa rather than with the stomach. However, the type of surface conformation of polyethylene glycol chains appears to have a great influence on the behaviour of these NPs. Theoretically, the traditional 'brush' polyethylene glycol corona would facilitate the penetration of the pegylated particles through the mucus layer and the subsequent adhesive interaction with the mucosa, which would promote their absorption by intestinal enterocytes. On the contrary, pegylated NPs with a 'loop' conformation would increase the time of residence of the adhered fraction of particles in the mucosa.
Subject(s)
Drug Delivery Systems , Maleates/chemistry , Nanostructures , Pharmaceutical Preparations/administration & dosage , Polyethylene Glycols/chemistry , Polyethylenes/chemistry , Adhesiveness , Administration, Intranasal , Administration, Oral , Animals , Enterocytes/metabolism , Epithelium, Corneal/metabolism , Intestinal Absorption , Maleates/metabolism , Nasal Mucosa/metabolism , Particle Size , Polyethylene Glycols/metabolism , Polyethylenes/metabolism , Rats , Surface PropertiesABSTRACT
Bioadhesive nanoparticles have been proposed as carriers for the oral delivery of poorly available drugs and facilitate the use of this route. This work summarises some experiments describing the bioadhesive potential of Gantrez nanoparticles fluorescently labeled with rhodamine B isothiocyanate. The adhesive potential of Gantrez was found to be stronger when folded as nanoparticles than in the solubilised form. Conventional nanoparticles displayed a tropism for the upper areas of the gastrointestinal tract, with a maximum of adhesion 30 min post-administration and a decrease in the adhered fraction along the time depending on the given dose. The cross-linkage of nanoparticles with increasing amounts of 1,3-diaminopropane stabilised the resulting carriers and prolonged their half-life in an aqueous environment; although, the adhesive capacity of nanoparticles, the intensity and the relative duration of the adhesive interactions within the gut as a function of the cross-linking degree. Finally, nanoparticles were coated with either gelatin or albumin. In the first case, the presence of gelatin dramatically decreased the initial capacity of these carriers to interact with the gut mucosa and the intensity of these phenomenons. In the latter, bovine serum albumin coated nanoparticles (BSA-NP) showed an important tropism for the stomach mucosa without further significant distribution to other parts of the gut mucosa.
Subject(s)
Maleates/chemistry , Nanoparticles/chemistry , Polyvinyls/chemistry , Surface Properties , Adhesiveness , Administration, Oral , Animals , Biological Availability , Dose-Response Relationship, Drug , Gastric Mucosa/metabolism , Intestinal Mucosa/metabolism , Maleates/administration & dosage , Maleates/pharmacokinetics , Models, Biological , Molecular Conformation , Nanoparticles/administration & dosage , Polymers/chemistry , Polyvinyls/administration & dosage , Polyvinyls/pharmacokinetics , RatsABSTRACT
The aim was to evaluate the potential of specific bioadhesive nanoparticles to increase the oral bioavailability of pre-systemic degraded drugs, using 5-fluorouridine (FURD) as model. For this purpose, poly(methylvinylether-co-maleic anhydride) nanoparticles (NP), NP coated with albumin (BSA-NP) and NP treated with albumin and 1,3-diaminopropane (BD-NP) were used. All the formulations displayed a similar size and drug loading. However, BSA-NP showed a tropism for the stomach, NP developed adhesive interactions with both the stomach and middle portions of the small intestine and BD-NP with the distal regions of the small intestine. These formulations were orally administered to laboratory animals and the FURD levels in plasma, tissues and urine were quantified at different times. From the urine data, the FURD bioavailability when loaded in either BSA-NP or NP was about 79% and 21%, respectively. For the control oral solution and BD-NP this parameter was 11% and 2%, respectively. FURD metabolism in gut was assessed by HPLC analysis of the lumen content. A FURD metabolite was found. Comparing the three nanoparticle formulations, the presence of the metabolite in the lumen contents was significantly higher for BD-NP than for NP and BSA-NP. In summary, the use of bioadhesive nanoparticles with tropism for the stomach mucosa may be considered as an adequate alternative to increase the bioavailability of some pre-systemic metabolised drugs.
Subject(s)
Adhesives/pharmacokinetics , Fluorine/pharmacokinetics , Nanotechnology/methods , Pyrimidines/pharmacokinetics , Adhesives/chemistry , Animals , Biocompatible Materials/pharmacokinetics , Biotransformation , Fluorine/chemistry , Male , Metabolic Clearance Rate/physiology , Pyrimidines/chemistry , Rats , Rats, WistarABSTRACT
This paper describes a bioanalytical method involving a simple liquid-liquid extraction for the simultaneous HPLC determination of the enantiomers of tramadol, the active metabolite O-desmethyltramadol (M1), and the other main metabolite N-desmethyltramadol (M2) in biological samples. Chromatography was performed at 5 degrees C on a Chiracel OD-R column containing cellulose tris(3,5-dimethylphenylcarbamate) as chiral selector, preceded by a achiral end-capped C8 column (LiChrospher 60-RP-selected B 5 microm, 250 mm x 4 mm). The mobile phase was a mixture of phosphate buffer containing sodium perchlorate (1 M) adjusted to pH 2.5-acetonitrile-N,N-dimethyloctylamine (74.8:25:0.2). The flow rate was 0.5 ml/min. Fluorescence detection (lambda(ex) 200 nm/lambda(em) 301 nm) was used. Fluconazol was selected as internal standard. The limit of quantitation of each enantiomer of tramadol and their metabolites was 0.5 ng/ml (sample size = 0.5 ml). The chiral conditions and the LC optimisation were investigated in order to select the most appropriate operating conditions. The method developed has also been validated. Mean recoveries above of 95% for each enantiomer were obtained. Calibration curves for tramadol enantiomers (range 1-500 ng/ml), M1 enantiomers (range 0.5-100 ng/ml), and M2 enantiomers (range 0.5-250 ng/ml) were linear with coefficients of correlation better than 0.996. Within-day variation determined on four different concentrations showed acceptable values. The relative standard deviation (R.S.D.) was determined to be less than 10%. This method was successfully used to investigate plasma concentration of enantiomers of tramadol, O-desmethyltramadol and N-desmethyltramadol in a pharmacokinetic study.
Subject(s)
Narcotics/blood , Narcotics/pharmacokinetics , Tramadol/blood , Tramadol/pharmacokinetics , Biotransformation , Chromatography, High Pressure Liquid , Dealkylation , Female , Humans , Hydrogen-Ion Concentration , Indicators and Reagents , Male , Reference Standards , Reproducibility of Results , Solutions , Stereoisomerism , TemperatureABSTRACT
We developed and validated an accurate, sensitive, precise and rapid HPLC method with UV detection for the determination of sirolimus in blood samples from renal, cardiac and hepatic transplants. This method overcomes most of the problems related to previously published assays using a narrow-bore column with base deactivated C18 reversed phase. Whole blood samples were purified by a combination of a precipitating blood matrix with zinc sulphate and a single step liquid-liquid extraction with acetone and 1-chlorobutane. Calibration curves (range 2.5-150 ng/ml), were linear with coefficients of correlation better than 0.996. The relative standard deviation was determined to be less than 8%. The present method has also been validated by a reference laboratory (St. George's Hospital Medical School, London, UK). More of 300 clinical samples have been analysed with this method.